Łukasz Magiera

2.2k total citations · 1 hit paper
10 papers, 1.4k citations indexed

About

Łukasz Magiera is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Łukasz Magiera has authored 10 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Łukasz Magiera's work include Peptidase Inhibition and Analysis (3 papers), Immunotherapy and Immune Responses (2 papers) and Immune Response and Inflammation (2 papers). Łukasz Magiera is often cited by papers focused on Peptidase Inhibition and Analysis (3 papers), Immunotherapy and Immune Responses (2 papers) and Immune Response and Inflammation (2 papers). Łukasz Magiera collaborates with scholars based in United Kingdom, Denmark and Germany. Łukasz Magiera's co-authors include Douglas T. Fearon, Matthew Kraman, James N. Arnold, James O. Jones, Edward W. Roberts, David A. Tuveson, Aarthi Gopinathan, Monika C. Brunner‐Weinzierl, Maike de la Roche and Holger Lingel and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Łukasz Magiera

8 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α

2010 918 citations Matthew Kraman, James N. Arnold et al. Science profile →

Peers

Countries citing papers authored by Łukasz Magiera

Since Specialization

Citations

This map shows the geographic impact of Łukasz Magiera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Łukasz Magiera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Łukasz Magiera more than expected).

Fields of papers citing papers by Łukasz Magiera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Łukasz Magiera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Łukasz Magiera. The network helps show where Łukasz Magiera may publish in the future.

Co-authorship network of co-authors of Łukasz Magiera

This figure shows the co-authorship network connecting the top 25 collaborators of Łukasz Magiera. A scholar is included among the top collaborators of Łukasz Magiera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Łukasz Magiera. Łukasz Magiera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Abstract LB458: Osimertinib treatment drives expression of TROP2, and combination treatment with datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, enhances its efficacy in PDX models of EGFR mutant non small-cell lung cancer 2025 ·Cancer Research ·(unknown), (unknown), Fernando Sánchez Calero, (unknown), Adina Hughes, Łukasz Magiera, Lucy Ireland, Nicolas Floc’h	0
2	Bayesian modeling for analyzing heterogeneous response in preclinical mouse tumor models 2024 ·Science Translational Medicine ·(unknown), Łukasz Magiera, Juliana Candido, (unknown), Jane Coates Ulrichsen, Jim Eyles, Elena Galvani, Natasha A. Karp	2
3	146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies 2024 ·European Journal of Cancer ·Julian R. Smith, Jelena Urosevic, S. Breanndan Moore, Łukasz Magiera, Lisa Bradshaw, Davide Gianni, Bharath Srinivasan, J.E. Debreczeni, C. W. Stubbs, Mercedes Vázquez–Chantada, Tao Hong, Anna Cronin, Karim Khan, Eve J. Wiseman, Douglas Ferguson, James T. Lynch, Hing Man Chan, (unknown), Stephen E. Fawell, Emma Dean	0
4	Embryonic FAP+ lymphoid tissue organizer cells generate the reticular network of adult lymph nodes 2019 ·The Journal of Experimental Medicine ·Alice E. Denton, Edward J Carr, Łukasz Magiera, (unknown), Douglas T. Fearon	42
5	Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery 2019 ·Journal for ImmunoTherapy of Cancer ·Molly A. Taylor, Adina Hughes, Josephine Walton, Anna Coenen-Stass, Łukasz Magiera, Lorraine Mooney, (unknown), Anna D. Staniszewska, Linda C. Sandin, Simon T. Barry, Amanda Watkins, Larissa S. Carnevalli, Elizabeth Hardaker	70
6	Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding 2015 ·eLife ·(unknown), (unknown), Michael J. Harrison, Łukasz Magiera, Clemens Hermann, (unknown), Antoni G. Wrobel, (unknown), (unknown), Søren Buus, Nicola Ternette, William Mwangi, Colin Butter, Venugopal Nair, (unknown), Richard Duggleby, J. Alejandro Madrigal, Pietro Roversi, Susan M. Lea, Jim Kaufman	95
7	Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1 2013 ·Cancer Immunology Research ·James N. Arnold, Łukasz Magiera, Matthew Kraman, Douglas T. Fearon	136
8	Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8 ⁺ T cell 2012 ·Proceedings of the National Academy of Sciences ·James Thaventhiran, Anja Hoffmann, Łukasz Magiera, Maike de la Roche, Holger Lingel, Monika C. Brunner‐Weinzierl, Douglas T. Fearon	65
9	Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α breakdown → 2010 ·Science ·Matthew Kraman, (unknown), James N. Arnold, Edward W. Roberts, Łukasz Magiera, James O. Jones, Aarthi Gopinathan, David A. Tuveson, Douglas T. Fearon	918
10	A New Pathway of Staphylococcal Pathogenesis: Apoptosis-Like Death Induced by Staphopain B in Human Neutrophils and Monocytes 2008 ·Journal of Innate Immunity ·(unknown), Krzysztof Guzik, Łukasz Magiera, Małgorzata Bzowska, (unknown), Ida B. Thøgersen, Jan J. Enghild, Jan Potempa	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact